Growth hormone and insulin-like growth factor-I as anabolic agents

Current Opinion in Clinical Nutrition and Metabolic Care

Volumn 1, Issue 3, 1998, Pages 257-262

  Welle, Stephen ^a,b  

^a UNIVERSITY OF ROCHESTER   (United States)

^b Monroe Community Hospital   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GLUCOCORTICOID; HUMAN GROWTH HORMONE; MUSCLE PROTEIN; SOMATOMEDIN C;

ADULT; AGING; CHRONIC KIDNEY FAILURE; HUMAN; METABOLISM; MUSCULAR DYSTROPHY; PATHOPHYSIOLOGY; PHYSIOLOGY; REVIEW;

ADULT; AGING; GLUCOCORTICOIDS; HUMAN GROWTH HORMONE; HUMANS; INSULIN-LIKE GROWTH FACTOR I; KIDNEY FAILURE, CHRONIC; MUSCLE PROTEINS; MUSCULAR DYSTROPHIES;

EID: 0032057737     PISSN: 13631950     EISSN: None     Source Type: Journal    
DOI: 10.1097/00075197-199805000-00004     Document Type: Article

References (58)

1. Pell JM, Bates PC. Differential actions of growth hormone and insulin-like growth factor-I on tissue protein metabolism in dwarf mice. Endocrinology 1992; 130:1942-1950.
2. Mauras N, Horber FF, Haymond MW. Low dose recombinant human insulin-like growth factor-I fails to affect protein anabolism but inhibits islet cell secretion in humans. J Clin Endocrinol Metab 1992; 75:1192-1197.
3. Fryburg DA. Insulin-like growth factor I exerts growth hormone- and insulin-like actions on human muscle protein metabolism. Am J Physiol 1994; 267:E331-E336.
4. Lo H-C, Ney DM. GH and IGF-I differentially increase protein synthesis in skeletal muscle and jejunum of parenterally fed rats. Am J Physiol 1996; 271:E872-E878.
5. De Boer H, Blok G-J, Van der Veen EA. Clinical aspects of growth hormone deficiency in adults. Endocrine Rev 1995; 16:63-86.
6. Russell-Jones DL, Weissberger AJ, Bowes SB, Kelly JM, Thomason M, Umpleby AM, et al. The effects of growth hormone on protein metabolism in adult growth hormone deficient patients. Clin Endocrinol 1993; 38:427-431.
7. Binnerts A, Swart GR, Wilson JHP, Hoogerbrugge N, Pols HAP, Birkenhager JC, et al. The effect of growth hormone administration in growth hormone deficient adults on bone, protein, carbohydrate and lipid homeostasis, as well as on body composition. Clin Endocrinol 1992; 37:79-87.
8. Jorgensen JOL, Vahl N, Hansen TB, Thuesen L, Hagen C, Christiansen JS. Growth hormone versus placebo treatment for one year in growth hormone deficient adults: increase in exercise capacity and normalization of body composition. Clin Endocrinol 1996; 45:681-688.
9. Johannsson G, Grimby G, Sunnerhagen KS, Bengtsson B-A. Two years of growth hormone (GH) treatment increase isometric and isokinetic muscle strength in GH-deficient adults. J Clin Endocrinol Metab 1997; 82:2877-2884. This study clearly shows beneficial effects of growth hormone replacement on body composition and strength in growth hormone deficient patients. The major importance is that the effects are sustained for a very long period of study.
10. Cuneo RC, Judd S, Wallace JD, Perry-Keene D, Burger H, Lim-Trio S, et al. The Australian multicenter trial of growth hormone (GH) treatment in GH-deficient adults. J Clin Endocrinol Metab 1998; 83:107-116.
11. Burman P, Johansson AG, Siegbahn A, Vessby B, Karlsson FA. Growth hormone (GH)-deficient men are more responsive to GH replacement therapy than women. J Clin Endocrinol Metab 1997; 82:550-555.
12. Woodhouse LJ, Ramyar L, Weiner D, Thomas SG, Asa SL, Ezzat S. Growth hormone (GH) replacement in GH-deficient adults results in altered muscle morphology and elevated local production of insulin-like growth factor-I (IGF-I). Abstracts of the 79th Annual Meeting of the Endocrine Society; 1997. pp. 79.
13. Evans WJ. What is sarcopenia? J Gerontol 1995; 50 (suppl A):5-8.
14. Yarasheski KE, Zachwieja JJ, Bier DM. Acute effects of resistance exercise on muscle protein synthesis rate in young and elderly men and women. Am J Physiol 1993; 265:E210-E214.
15. Welle S, Thornton C, Jozefowicz R, Statt M. Myofibrillar protein synthesis in young and old men. Am J Physiol 1993; 264:E693-E698.
16. Welle S, Thornton C, Statt M. Myofibrillar protein synthesis in young and old human subjects after three months of resistance training. Am J Physiol 1995; 268:E422-E427.
17. Rooyackers OE, Adey DB, Ades PA, Nair KS. Effect of age on in vivo rates of mitochondrial protein synthesis in human skeletal muscle. Proc Natl Acad Sci U S A 1996; 93:15364-15369.
18. Balagopal P, Rooyackers OE, Adey DB, Ades PA, Nair KS. Effects of aging on in vivo synthesis of skeletal muscle myosin heavy-chain and sarcoplasmic protein in humans. Am J Physiol 1997; 273:E790-E800.
19. Corpas E, Harman SM, Blackman MR. Human growth hormone and human aging. Endocrine Rev 1993; 14:20-39.
20. Lamberts SWJ, van de Beld AW, van der Lely A-J. The endocrinology of aging. Science 1997; 278:419-424.
21. Rudman D, Feller AG, Nagraj HN, Gergans GA, Lalitha PY, Goldberg AF, et al. Effects of human growth hormone in men over 60 years old. N Engl J Med 1990; 323:1-6.
22. Welle S, Thornton C, Statt M, McHenry B. Growth hormone increases muscle mass and strength but does not rejuvenate myofibrillar protein synthesis in healthy subjects over 60 years old. J Clin Endocrinol Metab 1996; 81:3239-3243.
23. Thompson JL, Butterfield GE, Marcus R, Hintz RL, Van Loan M, Ghiron L, et al. The effects of recombinant human insulin-like growth factor-I and growth hormone on body composition in elderly women. J Clin Endocrinol Metab 1995; 80:1845-1852.
24. Yarasheski KE, Zachwieja JJ, Campbell JA, Bier DM. Effect of growth hormone and resistance exercise on muscle growth and strength in older men. Am J Physiol 1995; 268:E268-E276.
25. Papadakis MA, Grady D, Black D, Tierney MJ, Gooding GAW, Schambelan M, et al. Growth hormone replacement in healthy older men improves body composition but not functional ability. Ann Intern Med 1996; 124:708-716.
26. Welle S, Thornton C. Insulin-like growth factor-I, actin, and myosin heavy chain messenger RNAs in skeletal muscle after an injection of growth hormone in subjects over 60 years old. J Endocrinol 1997; 155:93-97.
27. Butterfield GE, Thompson J, Rennie MJ, Marcus R, Hintz RL, Hoffman AR. Effect of rhGH and rhlGF-I treatment on protein utilization in elderly women. Am J Physiol 1997; 272:E94-E99. This study is the first to demonstrate that growth hormone and IGF-I can stimulate muscle protein synthesis in older subjects, in contrast to previous studies that had failed to find such an effect.
28. Taaffe DR, Pruitt L, Reim J, Hintz RL, Butterfield GE, Hoffman AR, et al. Effect of recombinant human growth hormone on the muscle strength response to resistance exercise in elderly men. J Clin Endocrinol Metab 1994; 79:1361-1366.
29. Holloway L, Butterfield GE, Hintz RL, Gesundheit N, Marcus R. Effects of recombinant human growth hormone on metabolic indices, body composition, and bone turnover in healthy elderly women. J Clin Endocrinol Metab 1994; 79:470-479.
30. Chan JM, Stampfer MJ, Giovannucci E, Gann PH, Ma J, Wilkinson P, et al. Plasma insulin-like growth factor-I and prostate cancer risk: a prospective study. Science 1998; 279:563-566. This study provides strong evidence that IGF-I may promote the risk of prostate cancer, which raises further concerns about the use of growth hormone or IGF-I replacement to promote muscle anabolism in older men.
31. Vittone J, Blackman MR, Busby-Whitehead J, Tsiao C, Stewart KJ, Tobin J, et al. Effects of single nightly injections of growth hormone-releasing hormone (GHRH 1-29) in healthy elderly men. Metabolism 1997; 46:89-96.
32. 2 in age-advanced men and women. J Clin Endocrinol Metab 1997; 82:1472-1479.
33. Horber FF, Haymond MW. Human growth hormone prevents the protein catabolic side effects of prednisone in humans. J Clin Invest 1990; 86:265-272.
34. Mauras N, Beaufrere B. Recombinant human insulin-like growth factor-I enhances whole body protein anabolism and significantly diminishes the protein catabolic effects of prednisone in humans without a diabetogenic effect. J Clin Endocrinol Metab 1995; 80:869-874.
35. Bennet WM, Haymond MW. Growth hormone and lean tissue catabolism during long-term glucocorticoid treatment. Clin Endocrinol 1992; 36:161-164.
36. Oehri M, Ninnis R, Girard J, Frey FJ, Keller U. Effects of growth hormone and IGF-I on glucocorticoid-induced protein catabolism in humans. Am J Physiol 1996; 270:E552-E558.
37. Berneis K, Ninnis R, Girard J, Frey BM, Keller U. Effects of insulin-like growth factor I combined with growth hormone on glucocorticoid-induced whole-body protein catabolism in man. J Clin Endocrinol Metab 1997; 82:2528-2534.
38. Bowes SB, Benn JJ, Scobie IN, Umpleby AM, Lowy C, Sonksen PH. Leucine metabolism in patients with Cushing's syndrome before and after successful treatment. Clin Endocrinol 1993; 39:591-598.
39. Bowes SB, Umpleby AM, Cummings MH, Jackson NC, Carroll PV, Lowy C, et al. The effect of recombinant human growth hormone on glucose and leucine metabolism in Cushing's syndrome. J Clin Endocrinol Metab 1997; 82:243-246.
40. Ding H, Gao X-L, Hirschberg R, Vadgama J, Kopple JD. Impaired actions of insulin-like growth factor 1 on protein synthesis and degradation in skeletal muscle of rats with chronic renal failure. J Clin Invest 1996; 97:1064-1075.
41. Garibotto G, Barreca A, Russo R, Sofia A, Araghi P, Cesarone A, et al. Effects of recombinant human growth hormone on muscle protein turnover in malnourished hemodialysis patients. J Clin Invest 1997; 99:97-105. This study clearly shows a direct anabolic action of growth hormone on muscle in hemodialysis patients. The mechanism - stimulation of protein synthesis without a change in proteolysis - was shown to be the same in these patients as has been described in some studies of normal volunteers.
42. Griggs RC, Jozefowicz R, Kingston W, Nair KS, Herr BE, Halliday D. Mechanism of muscle wasting in myotonic dystrophy. Ann Neurol 1990; 27:505-512.
43. Thornton CA, Griggs RC, Welle S, Forbes GB, Moxley RT. Recombinant human growth hormone (rhGH) treatment increases lean body mass in patients with myotonic dystrophy [abstract]. Neurology 1993; 43:A280.
44. Vlachopapadopoulou E, Zachwieja JJ, Gertner JM, Manzione D, Bier DM, Matthews DE, et al. Metabolic and clinical response to recombinant human insulin-like growth factor I in myotonic dystrophy - a clinical research center study. J Clin Endocrinol Metab 1995; 80:3715-3723.
45. Rifai Z, Welle S, Moxley RTI, Lorenson M, Griggs RC. Effect of prednisone on protein metabolism in Duchenne dystrophy. Am J Physiol 1995; 268:E67-E74.
46. Zdanowicz MM, Moyse J, Wingertzahn MA, O'Connor M, Teichberg S, Slonim AE. Effect of insulin-like growth factor I in murine muscular dystrophy. Endocrinology 1995; 136:4880-4886.
47. Zdanowicz MM, Teichberg S, O'Connor M, Moyse J, Slonim AE. Metabolic and structural effects of insulin-like growth factor-I and high protein diet on dystrophic hamster skeletal muscle. Proc Soc Exp Med Biol 1997; 215:168-173.
48. Lin E, Goncalves JA, Lowry SF. Efficacy of nutritional pharmacology in surgical patients. Curr Opin Clin Nutr Metab Care 1998; 1:41-50.
49. Carli F, Webster JD, Halliday D. Growth hormone modulates amino acid oxidation in the surgical patient: leucine kinetics during the fasted and fed state using moderate nitrogenous and caloric diet and recombinant human growth hormone. Metabolism 1997; 46:23-28.
50. Carli F, Webster JD, Halliday D. A nitrogen-free hypocalorio diet and recombinant human growth hormone stimulate postoperative protein synthesis: fasted and fed leucine kinetics in the surgical patient. Metabolism 1997; 46:796-800.
51. Hammarqvist F, Stromberg C, von der Decken A, Vinnars E, Wernerman J. Biosynthetic human growth hormone preserves both muscle protein synthesis and the decrease in muscle-free glutamine, and improves whole-body nitrogen economy after operation. Ann Surg 1992; 216:184-191.
52. Jurasinski CV, Vary TC. Insulin-like growth factor I accelerates protein synthesis in skeletal muscle during sepsis. Am J Physiol 1995; 269:E977-E981.
53. Mulligan K, Grunfeld C, Hellerstein MK, Neese RA, Schambelan M. Anabolic effects of recombinant human growth hormone in patients with wasting associated with human immunodefiency virus infection. J Clin Endocrinol Metab 1993; 77:956-962.
54. Lieberman SA, Butterfield GE, Harrison D, Hoffman AR. Anabolic effects of recombinant insulin-like growth factor-I in cachectic patients with the acquired immunodeficieny syndrome. J Clin Endocrinol Metab 1994; 78:404-410.
55. Schambelan M, Mulligan K, Grunfeld C, Daar ES, LaMarca AL, Kotler DP, et al. Recombinant human growth hormone in patients with HIV-associated wasting. Ann Intern Med 1996; 125:873-882. This study demonstrates not only an increase in lean body mass associated with growth hormone treatment in HIV-infected patients with unintentional weight loss, but also improvement in work capacity.
56. Carroll PV, Umpleby AM, Albany E, Jackson NC, Morgan-Hughes JA, Sonksen PH, et al. Growth hormone therapy may benefit protein metabolism in mitochondrial encephalomyopathy. Clin Endocrinol 1997; 47:113-117.
57. Frost RA, Lang CH, Gelato MC. Transient exposure of human myoblasts to tumor necrosis factor-α inhibits serum and insulin-like growth factor-I stimulated protein synthesis. Endocrinology 1997; 138:4153-4159.
58. Allen DL, Linderman JK, Roy RR, Grindeland RE, Mukku V, Edgerton VR. Growth hormone/IGF-I and/or resistive exercise maintains myonuclear number in hindlimb unweighted muscles. J Appl Physiol 1997; 83:1857-1861.